Physician profile
Michael S Phillips
NPI 1306823927
$4,439.39
in general payments reported to CMS, 2019-2025
29 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $767 · 2021: $454 · 2022: $535 · 2023: $531 · 2024: $590 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,125.94 | 2019-2025 | Eterna, Proclaim, Ionicrf |
| Nalu Medical, INC. | $399.33 | 2020-2025 | Nalu Neurostimulation System |
| Medtronic, INC. | $290.68 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Boston Scientific Corporation | $199.02 | 2019-2025 | Intracept |
| Saluda Medical Americas, INC. | $166.87 | 2024-2025 | Evoke |
| Mml US, INC. | $127.53 | 2023 | Reactiv8 |
| Medtronic USA, INC. | $101.36 | 2019-2020 | |
| Relievant Medsystems, INC. | $84.05 | 2022-2023 | Intracept |
| Averitas Pharma INC. | $83.56 | 2025 | Qutenza |
| Si-Bone, INC. | $80.19 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $79.45 | 2019-2025 | Belbuca |
| Vertiflex, INC. | $76.88 | 2019 | |
| Tersera Therapeutics LLC | $74.74 | 2019 | |
| Spinal Simplicity, LLC | $74.58 | 2024 | Ha Minuteman G3-R |
| Novartis Pharmaceuticals Corporation | $61.60 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.02 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $55.22 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $40.09 | 2019-2020 | |
| Vertos Medical, INC. | $39.77 | 2023-2024 | Mild Device Kit |
| Abbvie INC. | $39.33 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.16 | 2025 | |
| Biotronik Nro, INC. | $28.87 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.92 | 2023 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $19.98 | 2022 | |
| Electronic Waveform Lab, INC. | $19.86 | 2022 | |
| Ibsa Pharma INC. | $15.98 | 2021 | |
| Bioventus LLC | $14.96 | 2022 | |
| Curonix LLC | $14.76 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Allergan, INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.